A new study published in npj Mental Health Research suggests that U.S. Special Operations veterans treated with a combination of magnesium and ibogaine experience a rapid, self-directed form of psychological healing. The findings suggest that the treatment triggers a state of “auto-psychotherapy,” where patients revisit traumatic memories, reframe their life narratives, and feel a physical sense of brain repair.
Ibogaine is a powerful psychoactive substance derived from the root bark of the African shrub Tabernanthe iboga. While it has been used traditionally for centuries in West-Central Africa, it has gained attention in modern medicine for its potential to treat addiction and severe mental health conditions.
However, ibogaine interacts with the heart in ways that can be dangerous. To mitigate these risks, the treatment protocol in this study combined ibogaine with magnesium, a mineral that supports heart health and nervous system stability.
Previous observational studies have indicated that ibogaine can lead to reductions in symptoms of depression, anxiety, and substance use disorders. Despite these promising clinical outcomes, scientists have not fully understood what the patient actually experiences during the treatment that leads to recovery.
Most prior research focused on numbers and symptom checklists rather than the personal story of the patient. In their new study, the researchers aimed to bridge that gap. They sought to characterize the specific thoughts, emotions, and sensations veterans experienced to see if these subjective effects could explain their rapid recovery.
“A major motivation was the gap between strong clinical improvements being reported and limited understanding of patients’ lived healing processes,” said study author Clayton Olash, a psychiatry resident physician at the Medical University of South Carolina and affiliate researcher at Stanford University’s Brain Stimulation Laboratory.
“There is an active debate about whether psychedelic outcomes are primarily pharmacologic and neurobiological, or whether subjective experience and meaning-making are central to change. We wanted to characterize the lived psychological process in veterans who showed substantial recovery, and examine whether their reports aligned with established therapeutic frameworks.”
The study involved 30 male U.S. Special Operations Veterans. These participants had extensive histories of combat deployments and traumatic brain injuries, often caused by blast exposure. At the start of the study, the majority met the clinical criteria for post-traumatic stress disorder, and many suffered from major depressive disorder or alcohol use disorder. The participants traveled to a specialized clinic in Tijuana, Mexico, to receive the treatment.
The procedure was highly structured. Participants underwent medical screenings and preparatory sessions before the treatment day. On the day of dosing, they received intravenous magnesium to protect the heart. They then took oral ibogaine, with the dosage calculated specifically for their body weight. During the active phase of the drug, which can last many hours, the veterans lay on mats with eyeshades to encourage internal reflection. Medical staff monitored them closely throughout the process.
To capture the subjective nature of the experience, the researchers asked the veterans to answer three open-ended questions shortly after their treatment. The scientists analyzed these written narratives using a method called constructivist grounded theory. This is a research technique where scientists read the text multiple times to identify recurring patterns and group them into broader themes. This allows the data to tell a story rather than forcing it into pre-existing categories.
The analysis revealed that the veterans engaged in a process the scientists described as “accelerated auto-psychotherapy.” This term refers to a condensed, self-guided therapeutic process where the patient achieves deep insights without the immediate direction of a talk therapist. The researchers identified four primary domains of experience that defined this process.
The first domain was characterized as dialogic trauma re-appraisal. Veterans reported that they were able to recall painful or repressed memories with vivid clarity. However, unlike in a flashback where the person feels the original terror, these participants viewed the events with a sense of detachment. Many described an internal dialogue with a “guide” or “teacher” that helped them view their trauma from a new, less self-critical perspective. This allowed them to process events that had haunted them for decades.
“What surprised me most was the depth and consistency of reported psychological reprocessing across participants,” Olash told PsyPost.
The second theme involved an altered sense of self and mystical connectedness. Participants frequently described a dissolution of their ordinary ego or identity. Some reported feeling as though they were a “witness” to their own life, separating their core consciousness from their history and pain. This state often included feelings of awe and a sense of merging with a divine presence or the universe. This shift in perspective appeared to help veterans break free from rigid, negative beliefs about themselves.
The third theme centered on emotional resolution. The narratives contained frequent descriptions of intense emotional release. Veterans reported finding relief from chronic guilt, shame, and anger. In place of these heavy emotions, they experienced surges of forgiveness and compassion, both for themselves and for the people in their lives. This emotional breakthrough often led to a renewed desire to connect with family and friends.
The final theme was described as embodied healing. A significant number of participants reported physical sensations that they interpreted as their brains being repaired. They used metaphors involving electricity, rewiring, or scrubbing to describe the feeling of their neural pathways resetting. While this was a subjective sensation, it coincided with the veterans reporting improved mental clarity and a reduction in the physical symptoms associated with their brain injuries.
“I also found it remarkable how often participants linked subjective healing experiences to a felt sense of neural restoration, especially when previous work in this same cohort has shown that they experienced objective cognitive recovery from symptoms of TBI,” Olash said.
“In practical terms, these were not subtle changes in many cases, participants often described rapid and meaningful improvement in symptoms and functioning. Because this was qualitative work, our goal was depth and mechanism-rich description rather than effect size estimation. So the significance is best understood as clinically meaningful lived change that helps generate testable hypotheses for larger controlled studies.”
These themes suggest that ibogaine functions differently than standard psychiatric medications, which often work by suppressing symptoms. Instead, the substance appears to induce a dream-like state that lowers psychological defenses. This allows the brain to process suppressed information and reorganize its understanding of past trauma. The researchers noted that these experiences align with concepts found in established therapies, such as cognitive behavioral therapy and exposure therapy, but occur at a much faster rate.
“The key takeaway is that, in carefully structured settings, psychedelic treatment can involve deep psychological change and not just temporary intoxication,” Olash told PsyPost. “Participants described shifts in beliefs, emotional processing, trauma-related meaning, and sense of self that mapped onto concepts seen in psychotherapy. At the same time, these are powerful interventions with real risks, so this is not a casual or unsupervised treatment model.”
While the results provide insight into the potential of ibogaine, there are limitations to consider. The study population consisted exclusively of male Special Operations veterans, so the findings may not apply to women or civilians with different types of trauma. The data relied on retrospective accounts written days after the treatment, which can be subject to memory errors. Additionally, the study was open-label and observational, meaning there was no control group receiving a placebo for comparison.
It is also important to note that the researchers who analyzed the data were interpreting subjective narratives, which introduces a degree of potential bias. For instance, the study does not prove that the physical sensation of “brain rewiring” corresponds to actual biological repair.
“These qualitative findings are hypothesis-generating and should not be overgeneralized beyond the population and treatment conditions studied,” Olash said.
The scientists emphasize that ibogaine is a potent substance with serious risks if not administered in a medical setting. Future research aims to combine these narrative accounts with neuroimaging technology. This would allow scientists to see if the subjective feelings of healing map onto observable changes in brain structure and function. The researchers hope that by understanding these mechanisms, they can develop safer and more effective treatments for complex neuropsychiatric disorders.
“My long-term goal is to understand how acute altered states can be translated into durable clinical traits and recovery,” Olash explained. “That includes studying how psychedelic interventions might be paired with mindfulness, psychotherapy, and brain stimulation approaches to improve durability and personalization of outcomes. I am interested in mechanism-focused, clinically grounded research that can inform safer and more effective psychiatric care.”
“I think psychiatry is entering a period where novel interventions may meaningfully expand the treatment landscape for people who have not responded to conventional options. That said, careful screening, medical oversight, and rigorous science are essential. I hope this work encourages thoughtful public discussion and more high-quality research rather than hype.”
The study, “Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders,” was authored by Clayton Olash, Derrick Matthew Buchanan, Randi Brown, Afik Faerman, Kirsten Cherian, George Lin, David Spiegel, James J. Gross and Nolan Williams.
